Contineum Therapeutics (CTNM) Retained Earnings: 2023-2025
Historic Retained Earnings for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to -$162.2 million.
- Contineum Therapeutics' Retained Earnings fell 57.75% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.2 million, marking a year-over-year decrease of 57.75%. This contributed to the annual value of -$117.4 million for FY2024, which is 56.24% down from last year.
- According to the latest figures from Q3 2025, Contineum Therapeutics' Retained Earnings is -$162.2 million, which was down 8.56% from -$149.4 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Retained Earnings registered a high of -$75.1 million during Q4 2023, and its lowest value of -$162.2 million during Q3 2025.
- In the last 3 years, Contineum Therapeutics' Retained Earnings had a median value of -$110.1 million in 2024 and averaged -$114.6 million.
- Data for Contineum Therapeutics' Retained Earnings shows a maximum YoY tumbled of 61.37% (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Contineum Therapeutics' Retained Earnings stood at -$75.1 million in 2023, then crashed by 56.24% to -$117.4 million in 2024, then tumbled by 57.75% to -$162.2 million in 2025.
- Its Retained Earnings stands at -$162.2 million for Q3 2025, versus -$149.4 million for Q2 2025 and -$133.4 million for Q1 2025.